https://journals.eikipub.com/index.php/AIM-Medicine/issue/feed 2025-04-24T22:51:37-05:00 Preet Pal Singh Bhinder journals@eikipub.com Open Journal Systems <p>The <strong>Annals of Innovation in Medicine (AIM)</strong> is a publication that provides a platform for researchers, physicians, and other medical professionals to share their findings, discoveries, and insights on various medical topics with a focus on innovation. It serves as a valuable resource for healthcare professionals who want to stay up-to-date with the latest developments and advancements in the field of medicine, particularly in areas related to new technologies, techniques, and processes.</p> <p><strong>ISSN <a href="https://portal.issn.org/resource/ISSN/2977-0335">2977-0335</a></strong></p> <p>Frequency<strong>: Quarterly | </strong>Languages<strong>: English | </strong>Publisher<strong>: European Institute of Knowledge and Innovation (EIKI LTD.) | Other Info: Open-Access, Double peer-reviewed.</strong></p> https://journals.eikipub.com/index.php/AIM-Medicine/article/view/456 2025-04-24T22:51:37-05:00 Nehal A.M. Musa nehalahmedmaster@gmail.com Imad Eldin M. Taj Eldi omdataj64@gmail.com Huda M. Harron samarmusa78@gmail.com Bakri Y.M. Nour bakrinour@gmail.com Ibrahim O.M. Omer ibrahim70814@yahoo.com

<p>Malaria remains a significant public health concern in Sudan, particularly among children, with Plasmodium falciparum as the dominant species. Artemether-Lumefantrine (AL) is the recommended first-line treatment for uncomplicated malaria; however, rising treatment failure rates necessitate further evaluation. This study assessed the therapeutic efficacy of AL in children aged 6 months to 16 years at Wad-Medani Pediatric Teaching Hospital, Gezira State. A prospective single-arm interventional study was conducted, enrolling 80 patients and following 70 through a 28-day treatment regimen. Clinical assessments, parasitological responses, and adherence evaluations were performed. The results showed a cure rate of 91.5%, with significant adherence-related outcomes (p&lt;0.05). Early treatment failure (ETF) was observed in 5% of cases, with no late clinical or parasitological failures reported. Clinical pharmacist interventions improved awareness and adherence among healthcare providers and caregivers. The study concluded that AL remains highly effective for treating uncomplicated malaria in Sudan, although targeted interventions to enhance adherence are critical for sustained efficacy.</p>

2025-04-24T00:00:00-05:00 Copyright (c) 2025 Annals of Innovation in Medicine